Boxed warning added to Raptiva labeling
The labeling for Raptiva (efalizumab injection, from Genentech) has been updated to reflect FDA reports of serious infections in some psoriasis patients. The boxed warning highlights the risk of life-threatening infections including bacterial sepsis, viral meningitis, invasive fungal disease, progressive multifocal leukoencephalopathy (PML), and other opportunistic infections.
Raptiva is an immunosuppressant indicated for the treatment of moderate-to-severe chronic plaque psoriasis in adults who are candidates for systemic or phototherapy.
For more information visit www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm092089.htm.